News that Samsung Biologics is facing a probe by South Korean regulators over its valuation ahead of an initial public offering last year sent its share price down this week in Seoul.
South Korea’s Financial Supervisory Service is running a special audit of the drugs contract manufacturer, prompted by a Korean Institute of Certified Public Accountants review that found “unclear parts” in audits run before the IPO.
Get the full story on our sister site, Drug Delivery Business News.
The post Samsung Biologics slides on South Korean regulatory probe appeared first on MassDevice.